Special Feature "Drug Discovery Ecosystem
A New Map for Drug Discovery
New initiatives by industry, government, and academia are underway to strengthen Japan's drug discovery capabilities, including collaboration among companies at Shonan Eye Park, a new platform for industry-academia collaboration by AMED and JPMA, and startup support by METI. We are beginning to see the shape of a drug discovery ecosystem that will come to fruition through an all-Japan approach.
From JPMA
The Future of the Pharmaceutical Industry
Chairman Ueno and President Kinoshita in conversation
Japan's pharmaceutical industry is now at a turning point, triggered by the reform of the drug price system. JPMA Chairman Ueno and JPMA President Kinoshita spoke passionately about ways to restore drug discovery capabilities, including strengthening research collaboration with academia, promoting cooperation with start-ups, and accelerating overseas expansion.
The Pharmaceutical Industry from a Factual Perspective
The Reality of Drug Research and Development as Seen in Data
New drug development requires a long period of time and huge investment. The Office of Pharmaceutical Industry ResearchA comprehensive survey conducted for the first time in 11 years by the Pharmaceutical Manufacturers Association of Japan (PMAJ) reveals the reality of research and development. The results are rich in important implications for those of us working in the field of drug discovery.
Key words to keep in mind
First-in-Human Testing
Development of Implementation System
The "First-in-Human (FIH) Study" is the world's first study in which a drug is administered to humans. The establishment of a system to conduct this study will be a new turning point for drug development in Japan. We look at the significance and prospects of this project, from the elimination of drug lag/loss to the creation of a drug discovery environment.
My Committee
vol.1 Public Affairs Committee
JPMA has 12 committees and 6 specialized organizations. In this first issue, we focus on the Public Affairs Committee, which was established in 1978, and look at the forefront of activities to communicate the "now" of the pharmaceutical industry to society and the thoughts of the people who are responsible for these activities.
Topics
Introducing various topics within the association
From expectations for strengthening drug discovery, to the development of regulatory science, to new developments in countermeasures against infectious diseases, to the possibilities of Life Course Immunization, we look at the key events held by the Pharmaceutical Manufacturers Association of Japan (PMAJ). The latest trends in the industry and the issues we must face are revealed through the important conferences and forums held by JPMA.
Please click here to send us your comments on the renewed Newsletter. ／Readers' Questionnaire